Y-mAbs to Participate at Citi’s 2024 Global Healthcare Conference
Detailed price information for Y-Mabs Therapeutics Inc (YMAB-Q) from The Globe and Mail including charting and trades.
Analysts Issue Forecasts for YMAB FY2024 Earnings
Analysts at Brookline Capital Management issued their FY2024 earnings per share (EPS) estimates for shares of Y-mAbs ...
Promising Preclinical Results of Y-Mabs Therapeutics’ CD38 SADA Platform Justify Buy Rating
Canaccord Genuity analyst John Newman has maintained their bullish stance on YMAB stock, giving a Buy rating on December 4.Pick the best ...
ETF Daily News3d
Y-mAbs Therapeutics (NASDAQ:YMAB) Now Covered by Brookline Capital Management
Brookline Capital Management began coverage on shares of Y-mAbs Therapeutics (NASDAQ:YMAB – Free Report) in a research note ...
Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting
Detailed price information for Y-Mabs Therapeutics Inc (YMAB-Q) from The Globe and Mail including charting and trades.
Hosted on MSN6d
Brookline Capital Initiates Coverage of Y-mAbs Therapeutics (YMAB) with Buy Recommendation
Fintel reports that on December 5, 2024, Brookline Capital initiated coverage of Y-mAbs Therapeutics (NasdaqGS:YMAB) with a ...
Y-mAbs Therapeutics initiated with a Buy at Brookline
Brookline initiated coverage of Y-mAbs Therapeutics (YMAB) with a Buy rating and $17 price target Don't Miss our Black Friday Offers:Unlock ...